Target Price | HKD5.10 |
Price | HKD5.30 |
Deviation |
3.77%
register free of charge
|
Number of Estimates | 21 |
21 Analysts have issued a price target Sino Biopharmaceutical 2026 .
The average Sino Biopharmaceutical target price is HKD5.10.
This is
3.77%
register free of charge
HKD7.35
38.68%
register free of charge
HKD3.96
25.30%
register free of charge
|
|
A rating was issued by 27 analysts: 25 Analysts recommend Sino Biopharmaceutical to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Sino Biopharmaceutical stock has an average upside potential 2026 of
3.77%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion HKD | 31.59 | 35.84 |
10.18% | 13.46% | |
EBITDA Margin | 25.58% | 25.47% |
4.14% | 0.45% | |
Net Margin | 12.12% | 9.32% |
36.22% | 23.13% |
25 Analysts have issued a sales forecast Sino Biopharmaceutical 2025 . The average Sino Biopharmaceutical sales estimate is
This results in the following potential growth metrics:
25 Sino Biopharmaceutical Analysts have issued a net profit forecast 2025. The average Sino Biopharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share HKD | 0.21 | 0.19 |
61.54% | 9.52% | |
P/E | 28.44 | |
EV/Sales | 2.43 |
25 Analysts have issued a Sino Biopharmaceutical forecast for earnings per share. The average Sino Biopharmaceutical EPS is
This results in the following potential growth metrics and future valuations:
Sino Biopharmaceutical...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.